These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

985 related articles for article (PubMed ID: 12680244)

  • 1. Different expression of Fas and Fas ligand in tumor infiltrating and peripheral lymphocytes of patients with renal cell carcinomas.
    Elsässer-Beile U; Gierschner D; Welchner T; Wetterauer U
    Anticancer Res; 2003; 23(1A):433-7. PubMed ID: 12680244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced expression of IFN-gamma mRNA in CD4(+)or CD8(+)tumour-infiltrating lymphocytes compared to peripheral lymphocytes in patients with renal cell cancer.
    Elsässer-Beile U; Rindsfüser M; Grussenmeyer T; Schultze-Seemann W; Wetterauer U
    Br J Cancer; 2000 Sep; 83(5):637-41. PubMed ID: 10944605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma.
    Reichert TE; Strauss L; Wagner EM; Gooding W; Whiteside TL
    Clin Cancer Res; 2002 Oct; 8(10):3137-45. PubMed ID: 12374681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
    Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
    Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
    Bennett MW; O'Connell J; O'Sullivan GC; Brady C; Roche D; Collins JK; Shanahan F
    J Immunol; 1998 Jun; 160(11):5669-75. PubMed ID: 9605174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the activation status of tumor infiltrating and peripheral lymphocytes of patients with adenocarcinomas and benign hyperplasia of the prostate.
    Elsässer-Beile U; Przytulski B; Gierschner D; Grussenmeyer T; Katzenwadel A; Leiber C; Deckart A; Wetterauer U
    Prostate; 2000 Sep; 45(1):1-7. PubMed ID: 10960837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonal analysis of lymphocytes from tumor, peripheral blood, and nontumorous kidney in primary renal cell carcinoma.
    Kim TY; von Eschenbach AC; Filaccio MD; Hayakawa K; Parkinson DR; Balch CM; Itoh K
    Cancer Res; 1990 Sep; 50(17):5263-8. PubMed ID: 2143685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack.
    Donskov F; von der Maase H; Marcussen N; Hamilton-Dutoit S; Madsen HH; Jensen JJ; Hokland M
    Clin Cancer Res; 2004 Dec; 10(23):7911-6. PubMed ID: 15585624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semiquantitative analysis of Th1 and Th2 cytokine expression in CD3+, CD4+, and CD8+ renal-cell-carcinoma-infiltrating lymphocytes.
    Elsässer-Beile U; Grussenmeyer T; Gierschner D; Schmoll B; Schultze-Seemann W; Wetterauer U; Schulte Mönting J
    Cancer Immunol Immunother; 1999 Jul; 48(4):204-8. PubMed ID: 10431690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma.
    Finke JH; Rayman P; Alexander J; Edinger M; Tubbs RR; Connelly R; Pontes E; Bukowski R
    Cancer Res; 1990 Apr; 50(8):2363-70. PubMed ID: 2107973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
    Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
    Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors.
    Alexander JP; Kudoh S; Melsop KA; Hamilton TA; Edinger MG; Tubbs RR; Sica D; Tuason L; Klein E; Bukowski RM
    Cancer Res; 1993 Mar; 53(6):1380-7. PubMed ID: 8443817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytolytic effector mechanisms and gene expression in autologous graft-versus-host disease: distinct roles of perforin and Fas ligand.
    Miura Y; Thoburn CJ; Bright EC; Hess AD
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):156-70. PubMed ID: 14993881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-2 induces Fas ligand/Fas (CD95L/CD95) cytotoxicity in CD8+ and CD4+ T lymphocyte clones.
    Esser MT; Dinglasan RD; Krishnamurthy B; Gullo CA; Graham MB; Braciale VL
    J Immunol; 1997 Jun; 158(12):5612-8. PubMed ID: 9190908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of Fas(APO-1/CD95) in tumor-infiltrating and peripheral blood lymphocytes in patients with renal cell carcinoma.
    Cardi G; Heaney JA; Schned AR; Ernstoff MS
    Cancer Res; 1998 May; 58(10):2078-80. PubMed ID: 9605746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Difference in the expression of Fas/Fas-ligand and the lymphocyte subset reconstitution according to the occurrence of acute GVHD.
    Lee S; Chong SY; Lee JW; Kim SC; Min YH; Hahn JS; Ko YW
    Bone Marrow Transplant; 1997 Nov; 20(10):883-8. PubMed ID: 9404931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fas-related apoptosis in gastric adenocarcinoma.
    Lim SC
    Oncol Rep; 2003; 10(1):57-63. PubMed ID: 12469145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor infiltrating lymphocytes in uveal melanoma: a link with clinical behavior?
    Staibano S; Mascolo M; Tranfa F; Salvatore G; Mignogna C; Bufo P; Nugnes L; Bonavolontà G; De Rosa G
    Int J Immunopathol Pharmacol; 2006; 19(1):171-9. PubMed ID: 16569355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of Fas ligand (CD95L) by the toxic mistletoe lectins in human lymphocytes.
    Büssing A; Stein GM; Pfüller U; Schietzel M
    Anticancer Res; 1999; 19(3A):1785-90. PubMed ID: 10470116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.